Semaglutide and tirzepatide may be linked to ophthalmic complications due to rapid hyperglycemia correction, not drug toxicity. The study involved nine patients, with seven cases of nonarteritic ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.